Close

USPTO issues notice of allowance for GW Pharmaceuticals Sativex formulation spray device

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

Specialty Chemicals Solubility Enhances Drug Formulations

The need to improve the effectiveness, safety, and accessibility...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

The USPTO has issued a notice of allowance for GW Pharmaceuticals’ patent application regarding Sativex formulation spray device.

The patent alleges a metered valve pump spray device comprising a liquid cannabis extract, in propylene glycol and ethanol, which is adapted to spray a dose towards a patient’s sublingual mucosa.

GW chief executive officer Justin Gover said the notice of allowance for the Sativex delivery device follows notice of allowance for method of sublingual delivery of the Sativex pharmaceutical formulation.

“Not only does GW have claims directed to the method of sublingual delivery of the Sativex formulation, but it also has claims directed to the device within which it is contained,” Gover added.

“In total, we now have seven different patent families containing one or more pending or issued patents relating to Sativex.” The issued patent is expected to expire in March 2021.

 

Latest stories

Related stories

Small Molecule API Market Growth Analysis and Future Trends

Small Molecule API Market Size, Share, and Growth Analysis The...

Reviving Old Drugs with Specialty Intermediates in Europe

Drug development in the European pharmaceutical industry is undergoing...

Specialty Chemicals Solubility Enhances Drug Formulations

The need to improve the effectiveness, safety, and accessibility...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back